▼ bearish
Impact
PhasePhase 3 (completed; missed primary endpoint)
Time to marketTarget NDA submission September 2026; potential FDA approval Q3 2027 if accepted — but highly uncertain given the failed Phase 3.
seralutinib Updated Jul 1
What to watch
Watch for the public disclosure of the pre-NDA meeting outcome (mid-June 2026 meeting). If the FDA pushes back on filing, the stock could fall further. If the FDA allows the NDA submission to proceed, a September filing announcement could trigger a short-term bounce. Either way, this is a distressed penny stock, position sizing should account for potential total loss.
Bull case
- Despite narrowly missing the primary endpoint (p=0.032 vs α=0.025), seralutinib showed nominally significant improvement and stronger signals in higher-risk PAH subgroups, management is using this data along with the positive Phase 2 TORREY study to pursue FDA approval.
- The company completed a pre-NDA Type B meeting with the FDA in mid-June 2026 and is on track for a September 2026 NDA submission, with a potential Q3 2027 approval creating a speculative binary event.
- Gossamer raised ~$99M cash (extending runway into Q1 2027) and restructured $181M in convertible debt via an exchange, while dilutive, this buys time to execute the NDA strategy.
Bear case
- The Phase 3 PROSERA study definitively missed its primary endpoint, a 13.3m placebo-adjusted improvement in 6-minute walk distance failed the pre-specified statistical threshold (α=0.025). FDA approval for a drug that missed its primary endpoint is an uphill battle.
- The company is a single-asset biotech trading as a penny stock (~$0.16, down ~92% from pre-trial levels). The debt-restructuring deal issued up to 317.6 million new shares, massive dilution to existing holders.
- The second Phase 3 trial (SERANATA for PH-ILD) is paused indefinitely, eliminating the pipeline's second shot on goal until PROSERA implications are evaluated.